STOCK TITAN

Celularity Inc - CELU STOCK NEWS

Welcome to our dedicated news page for Celularity (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celularity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celularity's position in the market.

Rhea-AI Summary
Celularity Inc. (NASDAQ: CELU) will host an Investor and Analyst Research & Development Day on May 21, 2024, showcasing progress in placental-derived cell therapies, advanced biomaterial products, and future growth expectations. The event will feature key executives and a live webcast accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
Rhea-AI Summary
Celularity Inc. faces Nasdaq notice for late Form 10-K filing, risking non-compliance with listing requirements. The company must submit a plan to regain compliance within 60 days and faces potential delisting if not resolved by October 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Celularity Inc. announces the acceptance of its abstract 'Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials' at the ORS Tendon Conference 2024. The abstract explores the application of decellularized placental biomaterials in tendon management, focusing on biomechanical properties, immunomodulatory effects, and preclinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
none
Rhea-AI Summary
Celularity Inc. announces that its net sales for the first quarter of 2024 are exceeding expectations, with a projected fourth consecutive quarter of growth. The company is implementing cost reductions for 2024, including senior executive compensation cuts, to align incentives with shareholders. Celularity's advanced biomaterial products are experiencing faster adoption in the wound care market, leading to increased sales growth and potential applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Summary
Celularity Inc. (CELU) to present in vitro data on NK cell therapy programs at ASGCT Annual Meeting. The data suggest potential for addressing age-related diseases through senolytic agents. The company's placenta-derived NK cells show promise in targeting and removing damaged cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
conferences
-
Rhea-AI Summary
Celularity Inc. announced that the U.S. Centers for Medicare & Medicaid Services granted a Q code for Biovance® 3L, a placental-derived allograft for wound care. The Q code approval by CMS recognizes Biovance® 3L as a significant therapeutic option for treating wounds, potentially leading to increased adoption and growth for Celularity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
none
Rhea-AI Summary
Celularity Inc. plans to start a Phase 1/2 study in 2024 for its off-the-shelf, placental-derived cell therapy, PDA-002, targeting Facioscapulohumeral Muscular Dystrophy (FSHD). The company has received FDA clearance and seeks orphan drug designation. FSHD affects one in 8,000 people with no current cure, leading to severe muscle atrophy. Celularity aims to develop innovative therapies for challenging diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
-
Rhea-AI Summary
Celularity Inc. (NASDAQ: CELU) announces Dr. Robert Hariri's presentation on cellular therapy's potential to treat chronic conditions and extend lives at the ABUNDANCE Summit. The focus is on using placental-derived cell therapies to combat aging-related issues like immunosenescence and degenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
conferences
-
Rhea-AI Summary
Celularity Inc. (CELU) Founder and CEO, Dr. Robert Hariri, will present a keynote lecture at the Society for Brain Mapping and Therapeutics Annual World Congress discussing the potential of cellular immunotherapy in treating chronic conditions like cancer, multiple sclerosis, and Parkinson's disease. The keynote will focus on Celularity's mission to develop transformative therapies using placental-derived cells and biomaterial products. Dr. Hariri will address the broad applications of cellular immunotherapy beyond cancer, emphasizing its potential in neuroinflammatory and degenerative disorders. The company aims to lead in cellular therapeutics and collaborate with academic and industrial communities for research and investment opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.3%
Tags
conferences
Rhea-AI Summary
Celularity Inc. (NASDAQ: CELU) presented in vivo data on PT-CD16, a genetically modified cell therapy, at the AACR Annual Meeting 2024. The data showcased strong anti-tumor activity against gastric cancer. The company aims to combine cell therapies with approved antibodies for treating various cancers and conditions. The study revealed significant tumor volume reduction when PT-CD16VS was combined with trastuzumab compared to standard treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.67%
Tags
conferences
Celularity Inc

Nasdaq:CELU

CELU Rankings

CELU Stock Data

89.53M
9.49M
50.95%
14.67%
1.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Florham Park

About CELU

Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.